Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other EventsItem 8.01 Other Events.
On September7, 2017, we issued a press release, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 8.01 Financial Statements and Exhibits.
Set forth below is a list of the exhibits to this Current Report on Form 8-K.
|
Exhibit Number |
Description |
| 99.1 | Press release, dated September7, 2017 |
TYME TECHNOLOGIES, INC. ExhibitEX-99.1 2 d455450dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival in Metastatic Cancer Patients that Achieved Stable Disease – Stable disease patient group had failed a median of two prior lines of therapy and entered the trial with progressive metastatic disease – – Analysis suggests traditional RECIST response criteria may not reflect SM-88’s therapeutic benefit – -90% experienced clinical benefit by achieving complete response,…To view the full exhibit click here
About Tyme Technologies, Inc. (OTCMKTS:TYMI)
Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.
